Physician profile
Daniel Emilio Marquez
NPI 1154898914
$629.17
in general payments reported to CMS, 2019-2025
11 companies · $62.75 in 2025
The $62.75 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $269 · 2023: $81.25 · 2024: $82.55 · 2025: $62.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $226.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $284.37 | 2021-2025 | |
| Gilead Sciences, INC. | $91.90 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.80 | 2022-2024 | Caplyta |
| Indivior INC. | $40.91 | 2021-2022 | |
| Viiv Healthcare Company | $31.87 | 2022-2025 | Apretude |
| Organon LLC | $17.09 | 2023 | Nexplanon |
| Amgen INC. | $16.64 | 2021 | |
| Alkermes, INC. | $15.87 | 2025 | Aristada, Lybalvi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.08 | 2024 | Xifaxan |
| Insulet Corporation | $13.85 | 2025 | Omnipod |
| Lilly USA, LLC | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Marquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.